1219-Glioblastoma Organoids for Precision Oncology

This research introduces patient-derived glioblastoma organoids (GBOs) as a powerful tool for advancing personalized medicine and improving clinical outcomes for brain cancer patients. These three-dimensional models effectively mirror the histopathological and genetic profiles of the original tumors, offering a more accurate representation than traditional cell cultures. The study demonstrates that drug sensitivity testing using GBOs predicts patient survival and treatment response more reliably than current molecular markers like MGMT methylation. By utilizing this platform, researchers identified alternative therapies such as lazertinib and regorafenib for tumors that have developed resistance to standard chemotherapy. Furthermore, transcriptomic analysis of these organoids revealed complex mechanisms behind drug resistance, including DNA repair deficiencies and enhanced cell adhesion. Ultimately, this pipeline serves as a robust platform for precision oncology, accelerating the discovery of effective, tailored treatments for aggressive brain tumors.References:Park J, Qiu M, Cho E J, et al. Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma[J]. Cell Reports Medicine, 2026.前往小宇宙评论区与主播互动